351 related articles for article (PubMed ID: 1688341)
1. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
Bartoloni A; Colao MG; Orsi A; Dei R; Giganti E; Parenti F
J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.
Shonekan D; Mildvan D; Handwerger S
Antimicrob Agents Chemother; 1992 Jul; 36(7):1570-2. PubMed ID: 1324649
[TBL] [Abstract][Full Text] [Related]
3. The in vitro activity of ramoplanin (A-16686/MDL 62,198), vancomycin and teicoplanin against methicillin-susceptible and methicillin-resistant Staphylococcus spp.
O'Hare MD; Felmingham D; Grüneberg RN
Drugs Exp Clin Res; 1988; 14(10):617-9. PubMed ID: 2977587
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873.
Biavasco F; Lupidi R; Varaldo PE
Antimicrob Agents Chemother; 1992 Feb; 36(2):331-8. PubMed ID: 1534977
[TBL] [Abstract][Full Text] [Related]
5. Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus.
Maple PA; Hamilton-Miller JM; Brumfitt W
J Antimicrob Chemother; 1989 Apr; 23(4):517-25. PubMed ID: 2526111
[TBL] [Abstract][Full Text] [Related]
6. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.
Pohlod DJ; Saravolatz LD; Somerville MM
J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.
Biavasco F; Manso E; Varaldo PE
Antimicrob Agents Chemother; 1991 Jan; 35(1):195-7. PubMed ID: 1826593
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of the new glycopeptide decaplanin.
Neu HC; Chin NX; Niu WW
Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):458-62. PubMed ID: 1330562
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
Hodinka RL; Jack-Wait K; Wannamaker N; Walden TP; Gilligan PH
Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
[TBL] [Abstract][Full Text] [Related]
10. In-vitro studies with ramoplanin (MDL 62,198): a novel lipoglycopeptide antimicrobial.
O'Hare MD; Ghosh G; Felmingham D; Grüneberg RN
J Antimicrob Chemother; 1990 Feb; 25(2):217-20. PubMed ID: 2139436
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.
Lawrence T; Rotstein C; Beam TR; Gorzynski EA; Amsterdam D
Antimicrob Agents Chemother; 1993 Apr; 37(4):896-900. PubMed ID: 8494388
[TBL] [Abstract][Full Text] [Related]
12. [Susceptibility of Clostridium difficile strains to teicoplanin and ramoplanin].
Dworczyński A; Martirosian G; Meisel-Mikołajczyk F
Med Dosw Mikrobiol; 1993; 45(4):483-6. PubMed ID: 8189828
[TBL] [Abstract][Full Text] [Related]
13. Ramoplanin versus methicillin-resistant Staphylococcus aureus: in vitro experience.
Brumfitt W; Maple PA; Hamilton-Miller JM
Drugs Exp Clin Res; 1990; 16(8):377-83. PubMed ID: 2097143
[TBL] [Abstract][Full Text] [Related]
14. Activity of daptomycin against enterococci and coagulase-negative staphylococci (CNS): relationship between CNS susceptibility and slime production.
Marone P; Perversi L; Navarra A; Monzillo V; Sartirana E
J Chemother; 1993 Jun; 5(3):151-4. PubMed ID: 8396625
[TBL] [Abstract][Full Text] [Related]
15. Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations.
Low DE; McGeer A; Poon R
Antimicrob Agents Chemother; 1989 Apr; 33(4):585-8. PubMed ID: 2543286
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.
Machka K; Braveny I
Eur J Clin Microbiol; 1987 Feb; 6(1):96-9. PubMed ID: 3032613
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of LY264826 compared to other glycopeptides and daptomycin.
Chin NX; Neu HC
Diagn Microbiol Infect Dis; 1991; 14(2):181-4. PubMed ID: 1651826
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates from cancer patients.
Rolston KV; Dholakia N; Ho DH; LeBlanc B; Dvorak T; Streeter H
J Antimicrob Chemother; 1996 Aug; 38(2):265-9. PubMed ID: 8877541
[TBL] [Abstract][Full Text] [Related]
20. Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States.
Jones RN; Goldstein FW; Zhou XY
Antimicrob Agents Chemother; 1991 Mar; 35(3):584-6. PubMed ID: 1828137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
